Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)

NCT06291103 is registered in ClinicalTrials.gov with University Hospital, Rouen as lead sponsor.

NCT NCT06291103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)
Lead sponsor
University Hospital, Rouen
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
August 1, 2032
Enrollment
290 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection